AstraZeneca has entered an agreement with Johnson & Johnson to co-promote its prostate cancer drug abiraterone in Japan, expanding AZ’s presence in the country. Abiraterone was submitted for regulatory approval in Japan in July 2013. Abiraterone is currently marketed in the U.S. and Europe under the brand name Zytiga. Financial terms were not disclosed.
"This deal is a strong strategic fit for AstraZeneca, reinforcing both our focus on oncology as a core therapy area and Japan as one of our key growth drivers," said Marc Dunoyer, executive vice president for global products and portfolio strategy at AZ.
AZ, J&J in Prostate Cancer Drug Co-promotion Pact
Published October 11, 2013
blog comments powered by Disqus